300254.SHE Shanxi C&Y Pharmaceutical Group Co Ltd
- Market cap
- CNY 2.00B
- P/E
- 81.8x
- P/B
- 3.99x
- ROE
- 5.3%
- Dividend yield
- 0.95%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300254.SHE undervalued?
Graham numberThe Graham number of Shanxi C&Y Pharmaceutical Group Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanxi C&Y Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Shanxi C&Y Pharmaceutical Group Co Ltd yet.
Shanxi C&Y Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. Th…
Full company profileShanxi C&Y Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanxi C&Y Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 746M | 939M | 1.14B | 1.13B | 848M | 930M | 829M | 799M | 847M | 871M | 718M |
| Gross Profit | 493M | 649M | 868M | 853M | 584M | 640M | 578M | 540M | 563M | 587M | 462M |
| Operating Income | 24.1M | 28.8M | -14.8M | -41.1M | -315M | -79.6M | -115M | 40.2M | 65.0M | 115M | 68.0M |
| EBITDA | 107M | 107M | 84.9M | 72.6M | -179M | 47.4M | 14.3M | 141M | 149M | 172M | 84.7M |
| Net Income | 30.1M | 21.7M | 7.24M | 5.30M | -262M | -91.4M | -119M | 25.2M | 42.2M | 24.9M | 26.4M |
| EPS | 0.14 | 0.10 | 0.03 | 0.03 | -1.23 | -0.40 | -0.50 | 0.10 | 0.17 | 0.10 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 1.43B | 1.52B | 1.50B | 1.80B | 1.80B | 1.53B | 1.58B | 1.43B | 1.55B | 1.64B | 1.58B |
| Total Liabilities | 478M | 547M | 564M | 869M | 928M | 782M | 855M | 655M | 950M | 1.05B | 1.01B |
| Shareholders' Equity | 809M | 820M | 799M | 816M | 687M | 589M | 575M | 600M | 343M | 305M | 501M |
| Cash & Short-term Investments | 158M | 151M | 148M | 143M | 188M | 107M | 264M | 132M | 150M | 161M | 134M |
| Total Debt | 248M | 240M | 288M | 353M | 335M | 230M | 603M | 226M | 312M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 41.7M | 40.1M | 38.4M | 69.6M | -20.9M | 96.9M | 74.9M | 37.8M | 70.9M | 96.8M | - |
| Capital Expenditure | 50.8M | 101M | 29.6M | 18.5M | 31.5M | 36.9M | 26.8M | 33.9M | 51.5M | 34.3M | 33.0M |
| Free Cash Flow | -9.13M | -61.0M | 8.85M | 51.1M | -52.3M | 60.0M | 48.1M | 3.90M | 19.4M | 62.5M | 135M |
| Ratios | |||||||||||
| ROE | 3.7% | 2.6% | 0.9% | 0.6% | -38.2% | -15.5% | -20.6% | 4.2% | 12.3% | 8.2% | 5.3% |
| ROA | 2.1% | 1.4% | 0.5% | 0.3% | -14.6% | -6.0% | -7.5% | 1.8% | 2.7% | 1.5% | 1.7% |
| Net Profit Margin | 4.0% | 2.3% | 0.6% | 0.5% | -30.9% | -9.8% | -14.3% | 3.2% | 5.0% | 2.9% | 3.7% |
| Debt to Equity | 0.31x | 0.29x | 0.36x | 0.43x | 0.49x | 0.39x | 1.05x | 0.38x | 0.91x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanxi C&Y Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.95%
- Forward dividend
- -
- Payout ratio
- 76.3%
- Ex-dividend date
- Jul 11, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 19.0M | 0.07 | 76.3% |
| 2024 | CNY 12.3M | 0.05 | 29.2% |
| 2023 | CNY 13.3M | 0.06 | 52.8% |
| 2022 | CNY 11.9M | 0.05 | - |
| 2021 | CNY 14.7M | 0.06 | - |
| 2020 | CNY 20.8M | 0.10 | - |
| 2019 | CNY 4.17M | 0.02 | 78.7% |
| 2018 | CNY 35.9M | 0.17 | 496.1% |
| 2017 | CNY 24.8M | 0.11 | 114.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:10 on Jul 8, 2016.
Who owns Shanxi C&Y Pharmaceutical Group Co Ltd
- Insiders 21.02%
- Institutions 1.75%
- Public & others 77.23%
- Shares outstanding 271M
- Free float 217M
Shanxi C&Y Pharmaceutical Group Co Ltd company profile
- Company name
- Shanxi C&Y Pharmaceutical Group Co Ltd
- Ticker
- 300254.SHE
- ISIN
- CNE1000016D0
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 19, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,162
- Fiscal year end
- December
- Address
- Room 3605-3610, Xuhui, China, 200232
- Phone
- 86 21 6251 7032
- Website
- cy-pharm.com
About Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company's product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to ShanXi C&Y Pharmaceutical Group Co.,LTD. in September 2014. The company was founded in 2005 and is based in Xuhui, China.
Shanxi C&Y Pharmaceutical Group Co Ltd management
8- Mr. Qun ZhaoPresident & Director · born 1971
- Mr. Yanjie HeFinancial Director · born 1982
- Mr. Ying Min YuChief Engineer · born 1963
- Mr. Junxian YuSecretary, VP & Non-Independent Director · born 1967
- Mr. Bao Ping GuVice President · born 1972
- Mr. Kai Rui LuoVice President · born 1976
- Ms. Han YinVice President · born 1982
- Ya Li LiuChief Accountant